心力衰竭中的自:对机制和治疗影响的洞察
Magdalena Bielawska1, Marta Warszyńska1, Monika Stefańska1
1Department of Clinical Immunology, Jagiellonian University Medical College, University Children's Hospital, Wielicka 265, 30-663 Cracow, Poland.
Journal of cardiovascular development and disease
|August 25, 2023
概括
自对心脏健康至关重要,作为细胞清洁过程,打击心力衰竭. 了解它的作用和治疗潜力是未来治疗的关键.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 自是一种关键的细胞过程,用于清除受损的组件并维持心脏功能.
- 在心力衰竭中,自作为一种防止疾病进展的保护机制.
- 它的意义是在动物模型和人类心脏研究中确立的.
研究的目的:
- 审查自在心力衰竭进展中的作用.
- 巩固当前关于心力衰竭中自失调的知识.
- 探索针对自的治疗潜力.
主要方法:
- 关于心力衰竭中自的已发表数据的综合审查.
- 分析影响自的遗传和药理干预措施.
- 检查心肌细胞,心脏纤维细胞和内皮细胞中自的分子机制.
主要成果:
- 通过遗传或药理方法,自的放松调节会影响缺血性和非缺血性心力衰竭模型.
- 自会影响心肌细胞,心脏纤维细胞和内皮细胞中的关键细胞过程.
- 目前的研究强调了自在心力衰竭病理生理学中的复杂参与.
结论:
- 自在心力衰竭中起着双重作用,根据上下文可能具有保护性或有害性.
- 需要进一步的研究,以充分阐明针对心力衰竭的自治疗策略.
- 准自性对新的心力衰竭管理方法具有前景.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure Drugs: Inotropic Agents
621
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621


